Anti-Coagulation Factor XI Antibodies

Anti-Coagulation Factor XI Antibodies

Posted by Adam Awdish on

Innovative Grade US Origin Monkey Cynomolgus Plasma and Innovative Grade US Origin Monkey Rhesus Plasma from Innovative Research was used in the following study:


Anti-Coagulation Factor XI Antibodies

Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Vaishnavi Ganti, Mohammad Tabrizifard, Bianka Prinz

US Patent Pending
August 13, 2020

Thromboembolic disorders are one of the leading causes of death in the Western world despite the availability of numerous types of anticoagulants, like vitamin K antagonists (VKAs), heparins, and direct thrombin inhibitors. Though these drugs are effective in reducing thrombosis, they also come with some serious side effects. VKAs, for example, come with significant bleeding risk, have a slow onset and offset of action, and multiple dietary and drug interactions. Alternatively, non-vitamin K antagonist oral anticoagulants (NOACs) have demonstrated comparable efficacy to VKAs with less food and drug interactions and no need for monitoring, however, they still increase the risk of bleeding. This is largely because NOACs target proteins (coagulation Factor Xa (FXa) and thrombin) that are essential for normal coagulation (hemostasis).

In the classic waterfall model of the blood clotting cascade, coagulation is triggered by either the extrinsic (tissue factor (TF)-activated) pathway or the intrinsic (contact-activated) pathway, which both help in thrombin generation and fibrin formation. Thrombin further contributes to FXIa generation by direct activation of FXI in a feedback mechanism.

The antibodies described in this patent are capable of selectively binding to coagulation Factor XI (anti-FXI antibodies) and inhibiting blood coagulation and associated thrombosis without compromising hemostasis. Compositions include anti-coagulation Factor XI antibodies capable of binding to an epitope of the apple 3 (A3) domain of coagulation Factor XI. These antibodies exhibit neutralizing activity by inhibiting the conversion of the zymogen form FXI to its activated form (FXIa) under the action of FXIIa and inhibiting FXIa-mediated activation of FIX. The antibodies are useful for FXI inhibition, which may result in a clinically relevant anti-thrombotic effect with a reduced risk of bleeding complications, and thus an expanded therapeutic index compared to inhibition of more downstream clotting factors. The present invention provides an antibody or antigen binding fragment comprising at least the six complimentary determining regions (CDRs) of an anti-FXI antibody. In further embodiments, the antibody or antigen binding fragment binds the A3 domain of coagulation FXI and inhibits activation of FXI and/or Factor XIa-mediated activation of Factor IX.


Related products available from Innovative Research also include:

Innovative Grade US Origin Bovine Whole Blood

Innovative Grade US Origin Monkey Cynomolgus Serum

Single Donor Human Platelets ACD

  • Tags: Animal Plasma

    • The next big thing: it's what you do. The biological research materials you need to discover it? That's what we do! We love seeing how our products are being used in real-life applications and contributing to scientific acheivements every day. With thousands of published references and decades of proven results, you can count on us to help you source the high-quality biomaterials you need that will deliver reliable, consistent results - kit to kit, lot to lot, all study long. So what are you waiting for? All great discoveries start somewhere... yours starts with Innovative Research! Get in touch with our team today!

    Related Posts

    No Evidence of Autoimmunity to Human OX1 or OX2 Orexin Receptors in Pandemrix-Vaccinated Narcoleptic Children
    Pooled Human AB Serum Off The Clot Heat Inactivated from Innovative Research was used i...
    Read the Article
    A Proof-of-Concept, Two-Tiered Approach for Ricin Detection Using Ambient Mass Spectrometry
    Single Donor Human Urine and Single Donor Human Serum Off The Clot from Innovative Rese...
    Read the Article

    ← Older Post Newer Post →